Research programme: microtubule modulators - Reata Pharmaceuticals

Drug Profile

Research programme: microtubule modulators - Reata Pharmaceuticals

Alternative Names: Peloruside; Peloruside A; RTA 301

Latest Information Update: 12 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas Southwestern Medical Center; Victoria University of Wellington
  • Developer Reata Pharmaceuticals
  • Class Heterocyclic bicyclo compounds; Lactones
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events and the Cancer pharmacodynamics sections
  • 27 Apr 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section
  • 19 Apr 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top